Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

  • E. Livingstone
  • , H. Gogas
  • , L. Kandolf-Sekulovic
  • , F. Meier
  • , T. K. Eigentler
  • , M. Ziemer
  • , P. A.M. Terheyden
  • , A. H. Gesierich
  • , R. A. Herbst
  • , K. C. Kähler
  • , D. C. Ziogas
  • , Z. Mijuskovic
  • , M. Garzarolli
  • , C. Garbe
  • , A. Roesch
  • , S. Ugurel
  • , R. Gutzmer
  • , J. J. Grob
  • , F. Kiecker
  • , J. Utikal
  • C. Windemuth-Kieselbach, S. Eckhardt, L. Zimmer, D. Schadendorf*
*Korrespondierende/r Autor/-in für diese Arbeit
  • Universität Duisburg-Essen
  • Deutsches Krebsforschungszentrum
  • Harokopio University Athens
  • Military Medical Academy
  • Universitätsklinikum Carl Gustav Carus
  • Charite - Universitatsmedizin Berlin
  • Eberhard Karls Universität Tübingen
  • Universität Leipzig
  • Julius-Maximilians-Universität Würzburg
  • HELIOS Klinikum Erfurt
  • Christian-Albrechts Universität zu Kiel
  • Medizinische Hochschule Hannover
  • Johannes Wesling Klinikum Minden
  • Universität Aix-Marseille
  • Vivantes Auguste-Viktoria-Klinikum
  • Universität Mannheim
  • Alcedis GmbH

Abstract

Aim: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma. 

Methods: In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3 months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1). Primary outcome was PFS1 (time from start of run-in until PD1 or death). OS and safety were also assessed. 

Results: Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n = 69; Arm B, n = 66). Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9 months; hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.37–0.84; PStratified = 0.001). Median OS was not reached in either arm (HR 1.22; 95%CI, 0.69–2.16; PStratified = 0.389); 2-year OS was higher in Arm B versus Arm A (67%; 95%CI, 53–78 versus 58%; 95%CI, 45–70). Grade 3/4 AEs occurred in 55% of patients in Arm A and 64% in Arm B; treatment-related AEs led to discontinuation of any drug in 7% and 9% of patients, respectively. 

Conclusion: In patients with BRAFV600-mutated advanced melanoma who achieve tumour control with TT, early switch at 3 months to atezolizumab led to rapid loss of tumour control but provided a numerical OS benefit at 2 years compared with continued TT.

OriginalspracheEnglisch
Aufsatznummer112941
ZeitschriftEuropean Journal of Cancer
Jahrgang190
ISSN0959-8049
DOIs
PublikationsstatusVeröffentlicht - 09.2023

Fördermittel

This study was funded by F. Hoffmann-La Roche Ltd. Third party funds were provided by F. Hoffmann-La Roche for study co-ordination, documentation, monitoring and analysis. Vemurafenib, cobimetinib and atezolizumab were provided at no cost.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

DFG-Fachsystematik

  • 2.22-14 Hämatologie, Onkologie
  • 2.22-19 Dermatologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren